Tarsus Pharmaceuticals (TARS) Liabilities and Shareholders Equity (2019 - 2026)

Tarsus Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $581.1 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 16.05% year-over-year to $581.1 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 33.23% YoY), while the FY2025 annual figure was $562.2 million, up 49.12% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $581.1 million, up from $562.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $581.1 million in Q1 2026, with the low at $181.5 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $349.3 million (2024), against an average of $352.1 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity decreased 25.27% in 2023, then surged 99.47% in 2024.
• Tarsus Pharmaceuticals' Liabilities and Shareholders Equity stood at $227.9 million in 2022, then climbed by 16.51% to $265.5 million in 2023, then jumped by 42.0% to $377.0 million in 2024, then soared by 49.12% to $562.2 million in 2025, then advanced by 3.38% to $581.1 million in 2026.
• Business Quant data shows TARS's Liabilities and Shareholders Equity at $581.1 million in Q1 2026, $562.2 million in Q4 2025, and $534.6 million in Q3 2025.